lithospermic acid
lithospermic acid Basic information
- Product Name:
- lithospermic acid
- Synonyms:
-
- lithospermic acid
- 4-{(E)-2-[1-Carboxy-2-(3,4-dihydroxy-phenyl)-ethoxycarbonyl]-vinyl}-2-(3,4-dihydroxy-phenyl)-7-hydroxy-2,3-dihydro-benzofuran-3-carboxylic acid
- Aids071478
- Aids-071478
- Clinopodic acid H
- (2S,3S)-4-[(E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxoprop-1-enyl]-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-3-carboxylic acid
- 3-Benzofurancarboxylic acid, 4-[(1E)-3-[(1R)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]-3-oxo-1-propen-1-yl]-2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-, (2S,3S)-
- (2S,3S)-4-((E)-3-((R)-1-Carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carboxylic acid
- CAS:
- 28831-65-4
- MF:
- C27H22O12
- MW:
- 538.46
- Product Categories:
-
- chemical reagent
- pharmaceutical intermediate
- phytochemical
- reference standards from Chinese medicinal herbs (TCM).
- standardized herbal extract
- Mol File:
- 28831-65-4.mol
lithospermic acid Chemical Properties
- Melting point:
- 183-188 °C
- Boiling point:
- 862.6±65.0 °C(Predicted)
- Density
- 1.642±0.06 g/cm3(Predicted)
- storage temp.
- under inert gas (nitrogen or Argon) at 2-8°C
- solubility
- Soluble in methan
- form
- powder
- pka
- 2.77±0.10(Predicted)
- color
- White
- InChIKey
- UJZQBMQZMKFSRV-RGKBJLTCSA-N
- SMILES
- O1C2=C(O)C=CC(/C=C/C(O[C@@H](C(O)=O)CC3=CC=C(O)C(O)=C3)=O)=C2[C@H](C(O)=O)[C@H]1C1=CC=C(O)C(O)=C1
lithospermic acid Usage And Synthesis
Chemical Properties
Pale yellow crystals, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from the rhizome of Salvia miltiorrhiza, Lithospermum erythrorhizon of the Boraginaceae family.
Uses
Shikoric acid has the functions of improving kidney function, preventing and treating cardiovascular diseases, and anti-oxidation.
Biological Activity
Lithospermic acid, a plant-derived polycyclic phenolic carboxylic acid isolated from Salvia miltiorrhiza, has antioxidant and hepatoprotective activities against CCl4-induced acute and in vitro liver injury.
in vivo
Lithospermic acid (50 mg/kg, po for 6 days) exhibits cardioprotective efficacy against MI/R injury in mouse models[2].
Lithospermic acid (10-30 mg/kg, po, single dose) exhibits uric acid lowering and anti-inflammatory effects in rats hyperuricemia and gouty arthritis models[3].
| Animal Model: | C57BL/6 mouse MI/R injury models[2] |
| Dosage: | 50 mg/kg |
| Administration: | po for 6 days |
| Result: | Improved MI/R-induced cardiac dysfunction. |
| Animal Model: | Hyperuricemia and gouty arthritis model[3] |
| Dosage: | 10-30 mg/kg |
| Administration: | po, single dose |
| Result: | Reduced the serum uric acid and monosodium urate crystal-induced paw edema. |
target
ROS | ERK | MMP(e.g.TIMP) | DNA/RNA Synthesis | Caspase | TNF-α | HIV | SOD | GPx | Xanthine oxidas | MPO | MDA
lithospermic acidSupplier
- Tel
- 021-38218169 13681877033
- 2702713455@qq.com
- Tel
- +86-21-20908456
- sales@BioChemBest.com
- Tel
- 400-6009262 16621234537
- chenyj@titansci.com
- Tel
- 025-83697070
- info@chemlin.com.cn
- Tel
- 4009903999 13355009207
- 3007715519@qq.com